2-Hydroxyethyl 15-hydroxyoctadecanoate | 863485-92-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Hydroxyethyl 15-hydroxyoctadecanoate
• CAS: 863485-92-1
• 化学式: C₂₀H₄₀O₄
• 分子量: 344.5
• InChiKey: XDOCSXFXLXKRFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  24
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Forskolin compositions and methods for administration
  申请人：Roberts J. William

  公开号：US20060004090A1

  公开（公告）日：2006-01-05

  An administration method is provided, in which a composition comprising a forskolin 1α,9α-carbonate compound is administered to a human subject. According to an embodiment, the forskolin 1α,9α-carbonate compound has a skeletal structure of 8,13-epoxy-1α,6β,7β,9α-tetrahydroxylabd-14-en-11-one. A carbonyl group links the 1-position hydroxy oxygen and the 9-position hydroxy oxygen to one another for forming a carbonate ester ring. Hydrogen is appended to the 6-position hydroxy oxygen. A hydrogen or an acetyl group is appended to the 7-position hydroxy oxygen.

  提供了一种给药方法，其中将包含 forskolin 1α,9α-碳酸化合物的组合物给药于人体受试者。根据一个实施例，forskolin 1α,9α-碳酸化合物的骨架结构为 8,13-环氧-1α,6β,7β,9α-四羟基阿贝-14-烯-11-酮。一个羰基氧原子连接1位羟基氧原子和9位羟基氧原子以形成一个碳酸酯环。6位羟基氧原子附加了氢。7位羟基氧原子附加了氢或乙酰基团。
• PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
  申请人：Long Daniel D.

  公开号：US20130287730A1

  公开（公告）日：2013-10-31

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  这项发明提供了式(I)的化合物： 其中变量在规范中定义，或其药用盐，这些化合物是乙型肝炎病毒复制的抑制剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及用于制备这些化合物的工艺和中间体。
• HEPATITIS C VIRUS INHIBITORS
  申请人：McKinnell Robert Murray

  公开号：US20130287731A1

  公开（公告）日：2013-10-31

  The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  这项发明提供了以下式(I)或(II)的化合物： 其中变量在规范中定义，或其药用盐，这些化合物是乙型肝炎病毒复制的抑制剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及用于制备这些化合物的工艺和中间体。
• SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF
  申请人：BETTA PHARMACEUTICALS CO., LTD

  公开号：US20210340142A1

  公开（公告）日：2021-11-04

  A maleate, mesylate, benzene sulfonate, hydrochloride, phosphate, L-tartrate, L-malate, citrate, and fumarate of a compound represented by structural formula I, various crystal forms of each salt form, and a preparation method and application thereof.

  I的化合物的马来酸盐、甲磺酸盐、苯磺酸盐、氢氯酸盐、磷酸盐、L-酒石酸盐、L-苹果酸盐、柠檬酸盐和富马酸盐，每种盐形式的各种晶型，以及它们的制备方法和应用。
• 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3805223A1

  公开（公告）日：2021-04-14

  The present application relates to a 2,3-dihydro-1H-pyrrolizine-7-formamide derivative as a nucleoprotein inhibitor and a use in preparation of a drug for treating HBV related diseases. The present application specifically relates to a compound represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

  本申请涉及一种2,3-二氢-1H-吡咯烷-7-甲酰胺衍生物作为核蛋白抑制剂及其用于制备治疗HBV相关疾病的药物的应用。本申请特别涉及一种由公式(II)表示的化合物，以及其同分异构体或药用可接受的盐。